NCT04327089View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

March 23, 2021

Study Completion Date

March 23, 2021

Conditions
Phase 1
Interventions
DRUG

Setanaxib

Nox 1/4 inhibitor

Trial Locations (1)

38610

Eurofins Optimed, Gières

Sponsors
All Listed Sponsors
lead

Calliditas Therapeutics AB

INDUSTRY